Article
Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.
Journal of internal medicine - 1 Aug 2020
Christensen J G, Olson P, Briere T, Wiel C, Bergo M O
Abstract excerpt
The RAS genes, which include H, N, and KRAS, comprise the most frequently mutated family of oncogenes in cancer. Mutations in KRAS - such as the G12C mutation - are found in most pancreatic, half of colorectal and a third of lung cancer cases and is thus responsible for a substantial proportion of cancer deaths. Consequently, KRAS has been the subject of exhaustive drug-targeting efforts over the past 3-4...
Topics
- Antineoplastic Agents
- Clinical Trials as Topic
- Enzyme Inhibitors
- Humans
- Mutation
- Neoplasms
- Protein Prenylation
- Proto-Oncogene Proteins p21(ras)